Compliance Rate

Compliance Rate 100.0%
Compliant submissions 1
Incompliant submissions 0
Total trials 1

My Organizations' Clinical Trials

Showing 1550 of 2051 entries
View as:

A Dose Escalation Study of Adavosertib(MK1775) in Combination With 5-FU or 5-FU/CDDP in Patients With Advanced Solid Tumor (1775-005

Phase: N/A Priority: Normal
NCT ID: NCT01047007 Org: User:
Start: 01/18/10 End: 06/15/11 Due: 06/15/12

Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)

Phase: N/A Priority: Normal
NCT ID: NCT05119855 Org: User:
Start: 03/28/22 End: 12/12/23 Due: 12/12/24

Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)

Phase: N/A Priority: Normal
NCT ID: NCT03834493 Org: User:
Start: 07/28/19 End: 05/29/26 Due: 05/29/27

A Study of L-735,524 in HIV-Positive Children and Adolescents

Phase: N/A Priority: Normal
NCT ID: NCT00002351 Org: User:
Start: - End: - Due: -

Improving Management of Patients at High Risk for Osteoporotic Fractures (0000-038)

Phase: N/A Priority: Normal
NCT ID: NCT00139438 Org: User:
Start: 09/30/04 End: 06/30/05 Due: 06/30/06

Post-marketing Surveillance Study of Invasive Mycosis With Posaconazole (Study P04641)

Phase: N/A Priority: Normal
NCT ID: NCT00726609 Org: User:
Start: 01/31/06 End: 07/31/08 Due: 07/31/09

Intratumoral/Intralesional Administration of MK-4621/JetPEI™ With or Without Pembrolizumab in Participants With Advanced/Metastatic or Recurrent Solid Tumors (MK-4621-002)

Phase: N/A Priority: Normal
NCT ID: NCT03739138 Org: User:
Start: 12/18/18 End: 03/02/21 Due: 03/02/22

Study of MK-1248 With and Without Pembrolizumab (MK-3475) for Participants With Advanced Solid Tumors (MK-1248-001)

Phase: N/A Priority: Normal
NCT ID: NCT02553499 Org: User:
Start: 11/12/15 End: 10/17/18 Due: 10/17/19

Safety and Immunogenicity of V540B in Healthy Adults (V540B-002).

Phase: N/A Priority: Normal
NCT ID: NCT06623409 Org: User:
Start: 11/12/24 End: 11/20/26 Due: 11/20/27

A Drug-Drug Interaction Study Evaluating the Combination of IDX320 and IDX184 in Healthy Participants (MK-6844-002)

Phase: N/A Priority: Normal
NCT ID: NCT01157104 Org: User:
Start: 06/30/10 End: 08/31/10 Due: 08/31/11

Vicriviroc (SCH 417690) Treatment Protocol in Human Immunodeficiency Virus (HIV)-Infected Participants: A Rollover Study for ACTG Protocol A5211 (P04100)

Phase: N/A Priority: Normal
NCT ID: NCT00686829 Org: User:
Start: 06/30/05 End: 10/21/10 Due: 10/21/11

Safety, Tolerability, Efficacy and Pharmacokinetics of Imipenem/Cilastatin/Relebactam (MK-7655A) in Pediatric Participants With Gram-negative Bacterial Infection (MK-7655A-021)

Phase: N/A Priority: Normal
NCT ID: NCT03969901 Org: User:
Start: 10/08/19 End: 05/07/24 Due: 05/07/25

A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017) CORALreef HeFH

Phase: N/A Priority: Normal
NCT ID: NCT05952869 Org: User:
Start: 08/08/23 End: 04/07/25 Due: 04/07/26

A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-5823 in Overweight or Obese Participants Who Are Healthy or Have Type 2 Diabetes Mellitus (MK-5823-002)

Phase: N/A Priority: Normal
NCT ID: NCT01614782 Org: User:
Start: 06/30/12 End: 10/31/12 Due: 10/31/13

MK-1006 Single Dose Study in Japanese Type 2 Diabetes Patients (MK-1006-005)

Phase: N/A Priority: Normal
NCT ID: NCT00791661 Org: User:
Start: 11/30/08 End: 03/31/09 Due: 03/31/10

A Study to Evaluate the Effect of Food, Formulation, and a Proton Pump Inhibitor (PPI) on MK-1084 in Healthy Adult Participants (MK-1084-003)

Phase: N/A Priority: Normal
NCT ID: NCT06619314 Org: User:
Start: 09/20/23 End: 11/25/23 Due: 11/25/24

Growth Factor Signature (GFS) Pilot Study (MK0000-098)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00860535 Org: User:
Start: 06/30/09 End: 06/30/10 Due: 06/30/11

A Study of Indinavir Plus Ritonavir Plus Two NRTIs vs. Nelfinavir Plus Two NRTIs in HIV Positive Patients (0639-112)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00541463 Org: User:
Start: 01/31/01 End: 05/31/03 Due: 05/31/04

A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).

Phase: N/A Priority: Normal
NCT ID: NCT06307431 Org: User:
Start: 04/10/24 End: 06/08/32 Due: 06/08/33

A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

Phase: N/A Priority: Normal
NCT ID: NCT05933577 Org: User:
Start: 07/19/23 End: 09/26/30 Due: 09/26/31

MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)

Phase: N/A Priority: Normal
NCT ID: NCT05007106 Org: User:
Start: 09/16/21 End: 08/15/25 Due: 08/15/26

Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study

Phase: N/A Priority: Normal
NCT ID: NCT03933449 Org: User:
Start: 12/29/16 End: 03/14/22 Due: 03/14/23

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1029 in Participants With Mild to Moderate Asthma

Phase: N/A Priority: Normal
NCT ID: NCT01370317 Org: User:
Start: 06/01/11 End: 12/27/11 Due: 12/27/12

Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649)

Phase: N/A Priority: Normal
NCT ID: NCT01451437 Org: User:
Start: 11/18/11 End: 09/05/14 Due: 09/05/15

Pharmacokinetics of Midazolam, Dabigatran, Pitavastatin, Atorvastatin, and Rosuvastatin in Participants With Renal Insufficiency in the Presence and Absence of Rifampin (MK-0000-386)

Phase: N/A Priority: Normal
NCT ID: NCT03311841 Org: User:
Start: 03/01/18 End: 08/02/18 Due: 08/02/19